Idelalisib

Overview

Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).

Application

Products > Drug Discovery > Impurities > Anti-Neoplastic > Idelalisib and Impurities | Products > Drug Discovery > Inhibitor

Product Information

• Catalog No.: B0084-307712
• CAS No.: 870281-82-6
• Molecular Formula: C22H18FN7O
• Molecular Weight: 415.432
• Purity: > 95%
• Solubility: pH-dependent solubility ranging from <0.1 mg/mL at pH 5-7 to over 1 mg/mL at pH 2 under ambient conditions

Source

Original product source